GlassScriptPhysician profile
Tawfiq G Alam
NPI 1629092689
$4,196.43
in general payments reported to CMS, 2019-2025
19 companies · $576 in 2025
The $576 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2020: $138 · 2021: $136 · 2022: $633 · 2023: $1,033 · 2024: $1,396 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,005.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,505.08 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Takeda Pharmaceuticals U.S.A., INC. | $446.29 | 2019-2024 | Entyvio, Gattex |
| Janssen Biotech, INC. | $444.43 | 2020-2025 | Stelara, Tremfya, Remicade |
| Celgene Corporation | $370.37 | 2022-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $369.28 | 2022-2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $220.98 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $147.69 | 2022-2024 | Epclusa |
| Evoke Pharma, INC. | $140.17 | 2022-2023 | Gimoti |
| Pfizer INC. | $120.29 | 2019 | |
| Madrigal Pharmaceuticals | $118.24 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $114.78 | 2024 | |
| Eisai INC. | $70.67 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $36.64 | 2022 | |
| Braintree Laboratories, INC. | $19.61 | 2023 | Sutab, Suflave |
| Amgen INC. | $17.74 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.62 | 2020 | |
| Amarin Pharma, INC. | $13.11 | 2019 | |
| Clarus Therapeutics INC. | $12.34 | 2021 | |
| Allergan, INC. | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tawfiq Alam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.